Clene Inc. announces a registered direct offering of $4 million. The offering involves 1,219,513 shares priced at $3.28 each and is led by Chairman David Matlin and other existing shareholders.
Amount Raised
$4 Million
Round Type
Post-IPO Equity
Salt Lake CityBiotechnologyTherapeuticsPharmaceuticalBiopharmaInvestors
Description
Clene Inc. has priced a registered direct offering of 1,219,513 shares at $3.28 per share to existing shareholders, raising a total of $4 million. The offering is expected to close on September 17, 2026. Proceeds will support operations through mid-first quarter 2027 and fund various corporate purposes
Quick answer
Clene Nanomedicine raised $4 Million in a Post-IPO Equity round, dated September 15, 2026. Investors: Existing Stockholders, Company Directors, Company Officers, Kensington Capital Holdings and David Matlin. Clene Nanomedicine is based in Salt Lake City, Utah, United States.
- How much did Clene Nanomedicine raise?
- Clene Nanomedicine raised $4 Million in a Post-IPO Equity round on September 15, 2026.
- Who invested in Clene Nanomedicine?
- Existing Stockholders, Company Directors, Company Officers, Kensington Capital Holdings and David Matlin are named as investors in this round.
- What does Clene Nanomedicine do?
- Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and..
- Where is Clene Nanomedicine based and how big is it?
- Clene Nanomedicine is based in Salt Lake City, Utah, United States. Fundz records about 78 employees.
- Who are the decision-makers at Clene Nanomedicine?
- Fundz holds 1 contact at Clene Nanomedicine, including the Vice President, Translational Medicine. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Clene Nanomedicine that raised within 45 days of this round, from Fundz verified event records.
- Quanta Therapeutics raised an undisclosed amount (Series D) on October 24, 2026.
- Disc raised $422M (Post-IPO Equity) on October 20, 2026.
- Acta Pharmaceuticals raised $24M (Seed) on October 15, 2026.
- Os Therapies raised $7.2M on October 15, 2026.
- Ensho Therapeutics raised $7.3M on October 2, 2026.
- Breye Therapeutics raised $77M (Series A) on September 29, 2026.
Who to call at Clene Nanomedicine, and when
A new round usually means Clene Nanomedicine is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Clene Nanomedicine raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Clene Nanomedicine, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Clene Nanomedicine. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Clene Nanomedicine raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Clene Nanomedicine raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.